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Jishu Han,a,b Jingjing Zhang,a Meng Yang,a Daxiang Cui*a and
Jesus M. de la Fuente*a,c
Targeted imaging and tumor therapy using nanomaterials has stimulated research interest recently, but
the high cytotoxicity and low cellular uptake of nanomaterials limit their bioapplication. In this paper,
glucose (Glc) was chosen to functionalize Au nanoprisms (NPrs) for improving the cytotoxicity and cellular
uptake of Au@PEG-Glc NPrs into cancer cells. Glucose is a primary source of energy at the cellular level
and at cellular membranes for cell recognition. A coating of glucose facilitates the accumulation of
Au@PEG-Glc NPrs in a tumor region much more than Au@PEG NPrs. Due to the high accumulation and
excellent photoabsorbing property of Au@PEG-Glc NPrs, enhanced optoacoustic imaging of a tumor
in vivo was achieved, and visualization of the tumor further guided cancer treatment. Based on the
optical–thermal conversion performance of Au@PEG-Glc NPrs, the tumor in vivo was effectively cured
through photothermal therapy. The current work demonstrates the great potential of Au@PEG-Glc NPrs
in optoacoustic imaging and photothermal cancer therapy in future.
Introduction
Cancer is one of the most serious diseases that jeopardizes
human health and leads to death, amounting to 14.1 million
newly diagnosed cancer cases and 8.2 million cancer-related
deaths per year according to the report of the World Health
Organization.1 With the current development of scientific pro-
gress, multidisciplinary diagnoses and treatments are
researched to improve the efficacy of cancer treatment.2–5
Among various tumor imaging methods, optoacoustic
imaging, as an emerging biomedical technique, possesses
high spatial resolution and strong biochemical contrast
through the combined impact of ultrasound imaging and
optical imaging.6–8 Utilizing ultrasound and optical signals,
high resolution images in deep tissues and background-free
detection can be obtained without optical diffusion and
speckle artifacts.9,10 Therefore, optoacoustic imaging has been
rapidly developed for visualizing biological structures in bio-
medical fields, and various exogenous absorbers in the near-
infrared region known as contrast agents have also been
investigated for enhancing the imaging effect.11–13 Meanwhile,
among cancer treatment methods, photothermal therapy has
become a strong candidate in cancer treatment and therapy
since it can induce the targeted heat destruction of tumor
regions.14–16 Photothermal therapy refers to a photosensitizer
that is excited with near-infrared wavelength light, which is
more penetrative and less harmful to other cells and tissues.
Activation of the photosensitizer leads to an excited state that
then releases heat to kill the target cells.17,18 Now the research
aim is not only the improvement of diagnosis, imaging or
treatment methods, but also their combination in an all-in-
one system to realize highly efficient cancer treatment. To be
used in combination, both the contrast agent for optoacoustic
imaging and the photosensitizer for photothermal therapy
need to display near-infrared absorption. Consequently, it is of
great significance to choose one material that serves as a
contrast agent and photosensitizer for integrated optoacoustic
imaging and photothermal therapy.
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To date, two-dimensional nanomaterials such as carbon
nanotubes, nanocomposites, Bi2Se3 nanoplates, MoS2
nanosheets19–22 and so on have been widely applied in
imaging techniques and photothermal cancer therapy because
of their ultra-high specific surface area, strong near-infrared
optical absorbance and excellent biocompatibility. Now the
challenges faced by nanomaterials are efficient absorption of
higher wavelengths by changing the morphology, and also the
control of toxicity. Another promising candidate, Au-based
nanomaterials, possess lower cytotoxicity, higher photostabi-
lity, a surface plasmon resonance property that enhances
optical–thermal conversion effectiveness, and availability in
various morphologies for tuning the near-infrared absorption
region, which enable the aforementioned problems to be over-
come and extend their applications in photothermal
therapy.23–28 In particular, because of their tunable absorption
wavelengths, Au nanomaterials have become one of the most
suitable and stable photoabsorbing agents for optoacoustic
imaging, thus obtaining high quality images of tumor
regions.29–31
Current efforts in controlling the size and shape of Au
nanomaterials with near-infrared absorption come with the
problem of the usage of highly cytotoxic surfactants such as
cetyltrimethylammonium bromide (CTAB) in standard seed-
mediated growth methods,32–35 which thus affects the cytotoxi-
city and cellular uptake behavior. Therefore, the employment
of CTAB to prepare Au nanostructures should be avoided. The
strategy of preparing high quality Au nanoprisms (NPrs) free of
CTAB has been developed in our previous research.36 More-
over, another problem is cellular uptake in the biosystem. A
coating of poly(ethylene glycol) (PEG) is usually chosen to
improve the stability of Au nanomaterials and maintain longer
circulation time in the biosystem.37,38 However, the difference
in cellular uptake of PEG coated nanomaterials between
cancer cells and normal cells is not obvious, thus surface
coating materials tending towards cellular uptake should be
used for imaging and photothermal therapy in tumor regions.
Biological molecules such as peptides, oligonucleotides and
carbohydrates have become promising candidates to modify
nanomaterials due to their vital functions in living
systems.39,40 Glucose, as a carbohydrate, has many advantages
such as being easy to work with and inexpensive, causing no
increase of nanomaterial hydrodynamic size and having no
influence on conjugation with other molecules because of its
small size.41 Particularly, glucose is a primary source of energy
at the cellular level and at cellular membranes for cell reco-
gnition.42 A coating of glucose can improve cellular uptake of
nanomaterials into cancer cells.42,43 So on the basis of our
success in synthesizing various Au nanomaterials in aqueous
solution,36 in this work, we demonstrate a facile and feasible
method to synthesize Au NPrs in aqueous solution on the
basis of a one-pot reduction of Au ions using sodium thio-
sulfate. The efficient absorption of near-infrared wavelengths
is achieved due to the high anisotropic shape of the NPrs.
Without the usage of the surfactant CTAB, the cytotoxicity of
the Au NPrs obviously lowers, and the glucose coating effec-
tively improves cancer cellular uptake, thus giving the as-
prepared Au NPrs an excellent performance for applications in
optoacoustic imaging and photothermal cancer therapy.
Experimental section
Materials
Hydrogen tetrachloroaurate(III) hydrate (HAuCl4·4H2O),
sodium thiosulfate (Na2S2O3), NaBH4 (96%), KI (98%), NaOH
(99%) and all the other chemicals used were purchased from
the Sinopharm Chemical Reagent Co., Ltd. N-Hydroxysulfo-
succinimide (NHS), 1-ethyl-3-[3-dimethylaminopropyl] carbodii-
mide hydrochloride (EDC), glucose (4-aminophenyl
β-D-glucopyranoside, Glc), and 2-(N-morpholino)ethanesulfo-
nic acid (MES) were purchased from Sigma-Aldrich and used
as received. HS–C2H4–CONH–PEG–O–C3H6–COOH (HS–PEG–
COOH, MW = 5000 g mol−1) was obtained from Rapp-
Polymere.
Synthesis of Au nanoprisms
The synthesis of aqueous Au NPrs followed a modified prepa-
ration by Pelaz et al.36 In brief, aqueous Au NPrs were prepared
by dropwise adding 12 mL of freshly prepared 0.5 mM
Na2S2O3 solution and 32.7 μL of 0.01 M KI to 10 mL of 2 mM
HAuCl4 solution. The solution was mildly stirred for 9 min.
Then, 2 mL of 0.5 mM Na2S2O3 solution was added and the
final solution was stirred for 90 min.
Synthesis of PEGylated Au NPrs
Au NPrs were stabilized with HS–PEG–COOH modification.
Briefly, 1 mg of PEG was added into 10 mL of the prepared Au
NPr solution. The pH was adjusted to 12.0 with 2 M NaOH.
Subsequently, the solution was sonicated for 1 hour at 60 °C.
The PEGylated Au NPrs were purified by centrifugation at
6000 rpm for 10 min three times.
Synthesis of Au@PEG-Glc NPrs
The PEGylated Au NPrs were functionalized with glucose to
promote cellular uptake. Typically, 1 mg of the PEGylated Au
NPrs was dispersed in 2 mL of MES buffer (pH = 6.0) and incu-
bated with 0.5 mg of EDC and 1 mg of NHS for 20 min. The
activated Au NPrs were centrifuged at 6000 rpm for 10 min to
remove the excess EDC and NHS, and then incubated with
0.5 mg of 4-aminophenyl β-D-glucopyranoside for 2 hours. The
Glc-functionalized NPrs were washed three times by
centrifugation.
Characterization
UV-visible absorption spectra were obtained using a Varian
Cary 50 spectrophotometer (Varian Inc., Palo Alto, CA, USA).
Field emission scanning electron microscopy (FESEM) was
conducted using a Zeiss Ultra electron microscope operated at
30 kV. FTIR spectra were taken using a Nicolet 6700 spectro-
meter (Thermo Electron Corporation, Madison, WI, USA)
using KBr pellets. Cells were observed using a fluorescence
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microscope (NIKON TS100-F), and imaged using a GE HDX 3.0
T MR imaging instrument equipped with ParaVision 3.0
software. Photoacoustic (PA) imaging of the probes was
accomplished using an Endra Nexus 128 PA scanner.
Cell culture and MTT assay
The human gastric cancer cell line MGC-803 cells were incu-
bated at 37 °C (5% CO2) in Dulbecco’s Modified Eagle’s
Medium (DMEM, HyClone) supplemented with 10% (vol/vol)
fetal bovine serum (Gibco) and 100 U mL−1 penicillin–strepto-
mycin. The MTT assay was carried out to investigate the toxi-
city of the as-prepared NPrs. In brief, MGC-803 cells were
seeded in a 96-well plate at a density of 5000 cells per well and
cultured overnight. The cells were incubated with serial con-
centrations of Au@PEG or Au@PEG-Glc NPrs for 24 hours.
Then, the cells were washed with PBS and the medium was
removed. Cytotoxicity was evaluated by a standard MTT assay.
Cell viability = (OD570 nm of the experimental group/
OD570 nm of the control group) × 100%, and the cell viability
of the control group was denoted as 100%.
In vitro photothermal ablation of MGC-803 cells
The MGC-803 cells were seeded into 96-well plates and incu-
bated for 24 h to allow the cells to be attached. Then, the
medium was carefully removed and fresh medium containing
different concentrations of Au@PEG or Au@PEG-Glc NPrs was
added into each well. After incubation for another 24 h, the
cells were washed to remove non-internalized NPrs and irra-
diated for different times by an 808 nm laser with an output
power density of 0.5 W cm−2. Then, the cells were incubated
for an extra 12 hours and cell viability was measured via the
MTT assay according to the procedure described above.
Simultaneously, green fluorescent protein (GFP)-transfected
MGC-803 cells were incubated and treated in the same way as
MGC-803 cells, then Propidium Iodide (PI) was used to stain
dead cells before observation by fluorescence microscopy.
In vivo optoacoustic imaging
Animal experiments were performed according to Guidelines
for Animal Care and Use Committee, Shanghai Jiao Tong Uni-
versity. Male athymic nude mice were obtained from Shanghai
LAC Laboratory Animal Co. Ltd, Chinese Academy of Sciences
(Shanghai, China). MGC-803 cells (1 × 106) were injected sub-
cutaneously into the right posterior flank area of male nude
mice aged 4 to 5 weeks. Tumors were allowed to grow to a dia-
meter of approximately 5 mm. MGC-803 cell tumor-bearing
nude mice were first anaesthetized by intraperitoneal injection
of pentobarbital sodium (40 mg kg−1), then a PBS solution of
Au@PEG or Au@PEG-Glc NPrs (100 μL, 1 mg mL−1) was intra-
venously injected into the mice. Then, the imaging target
(tumor) was well mounted in the protruding top of the bowl.
The image position was consistent to facilitate comparisons.
The protruding top of the bowl was immersed in water and the
interface between the slot and imaging target was free of
bubbles, providing excellent photoacoustic signal transduc-
tion. Finally, optoacoustic imaging of the image target was
acquired according to different injection times. Pre-injection
scans were used as controls.
In vivo photothermal imaging
MGC-803 cell tumor-bearing nude mice were first anaesthe-
tized by intraperitoneal injection of pentobarbital sodium
(40 mg kg−1), then a PBS solution of Au@PEG or Au@PEG-Glc
NPrs (100 μL, 1 mg mL−1) was intravenously injected into the
mice. Mice intravenously injected with PBS (100 μL) were used
as a control. After 24 hours, the tumor site was exposed to an
808 nm laser with an output power density of 0.5 W cm−2 for
5 min. During the process of laser radiation, temperature and
whole-body infrared images were captured by a thermal
imaging camera (Testo 875-1, Germany) at different time
points.
The tumor size of all the mice was measured and pictures
of the mice were taken at pre-determined time points. The
length and width of the tumors were measured using a digital
vernier caliper and the tumor volumes were calculated accord-
ing to the formula (tumor length × (tumor width)2)/2.
Results and discussion
As mentioned in the Experimental section, the Au NPrs are
synthesized in HAuCl4 solution through stepwise addition of
sodium thiosulfate. For a typical synthesis of Au NPrs, 20 mL
of aqueous solution containing 2 mM HAuCl4 is mixed with
0.5 mM Na2S2O3 solution and 0.1 M KI under vigorous stirring.
The addition makes the mixture gradually turn from pale
brown to brownish black. After 9 min, additional 0.5 mM
Na2S2O3 solution was added dropwise and the mixture was
kept stirring for 60 min to maintain the growth of Au NPrs.
Fig. 1a shows the UV-vis absorption spectrum of the Au NPrs
with a major plasmon band at 845 nm, corresponding to the
in-plane dipolar band of the Au NPrs. The band at 530 nm is
attributed to the byproducts of the Au nanoparticles.44 From
the SEM image and AFM measurement, it is found that the as-
prepared Au NPrs are flat NPs with three congruent edge
lengths of 94 nm and thicknesses of 10 nm (Fig. 1b, c and e).
Compared with nanorods, nanocubes, or nanospheres, the tri-
angular shaped structure with high truncations and aspect
ratio and three tips displays stronger electromagnetic field
enhancement and provides more distinct plasmon resonance
in the near-infrared region.45–49 High-resolution TEM shows
that the triangular faces are [111] with a lattice spacing of
1.44 Å, consisting of the (220) plane of fcc Au (Fig. 1d),50 and
electron diffraction analysis of an individual gold nanoprism
shows that it is single crystalline and that the flat top and
bottom faces are [111] facets (Fig. 1f).51 Due to no surfactant
being added in our experiment, the colloidal syntheses of tri-
angular nanoprisms tend to yield some percentage of nano-
hexagons or nanodisks.52,53 Based on this, it is necessary to
purify the NPrs through centrifugation. Fig. S1† shows that
centrifugation can remove smaller nanostructures and make
the NPrs more homogeneous.
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To further increase the colloidal stability of Au NPrs, the
NPrs were modified with bifunctional polyethylene glycol. As
shown in the TEM image, the Au NPrs are covered with a shell
with low contrast, since the contrast of polymer materials is
usually worse than that of inorganic materials (Fig. S2†). The
coating of the PEG layer enhances the colloidal stability of the
Au NPrs obviously, thus avoiding morphology variation toward
spherical particles and final aggregation.54 UV-vis spectra also
exhibit unchanged absorption properties (Fig. S3†). To
increase the biocompatibility and cellular uptake for further
biological application, glucose is chosen to bond to the
surface of the Au@PEG NPrs. Glucose is one of the most
important molecules in the biosystem as it is a primary source
of energy at the cellular level. Cancer cell growth is heavily
dependent on increased glucose metabolism.42,43 Moreover,
overexpression of membrane glucose transporters such as
GLUT-1 in human cancers causes increased glucose utilization
in tumor cells.55 So, a coating of glucose can increase bio-
compatibility and cellular uptake, and reduce cytotoxicity effec-
tively for further biological application.56 UV-vis absorption
and FTIR spectra of the Au@PEG NPrs and Au@PEG-Glc NPrs
are compared to prove the formation of an amido bond
(Fig. 2). The absorption peak at 280 nm indicates the existence
of glucose (Fig. S4†), and is the characteristic absorption peak
of the phenyl group from 4-aminophenyl β-D-glucopyranoside,
and the changes in the FTIR spectra illustrate the formation of
an amido bond between PEG and glucose. Enhanced structural
stability and biocompatibility will broaden the practical
applications of Au@PEG-Glc NPrs in optoacoustic imaging
and photothermal therapy.
As mentioned above, Au nanomaterials can absorb NIR
light and transform the energy into heat.23–28 Au NPrs with
high truncations and aspect ratio and three tips possess
enhanced plasmon resonance in the near-infrared region.45–49
They are expected to be an efficient nanoheater to kill cancer
cells. The photothermal conversion performance is monitored
by the temperature change of 0.5 mL of Au@PEG-Glc NPr solu-
tion (Fig. 3). NPr solutions of concentrations varying from
5 μg mL−1 to 160 μg mL−1 were irradiated under an 808 nm
laser with a density of 0.5 W cm−2. The temperature increased
obviously during the first 5 minutes and kept steady
subsequently. The temperature increment rises from 12.4 to
20.2 °C after laser irradiation. Actually, the temperature
Fig. 1 UV-vis absorption spectrum (a), SEM image (b), size distribution
(c) and TEM image (inset: HRTEM image of the top-facet of a NPr) of Au
NPrs (d); height profile along the solid line in the AFM image (inset) of a
single Au NPr (e) and electron diffraction pattern of the top of a single
prism (f ).
Fig. 2 (a) The evolution of the UV-vis absorption of Au NPrs without
modification (black), modified with PEG (blue), and modified with
glucose (red). (b) FTIR spectra of the Au@PEG-COOH and Au@PEG-Glc
NPrs.
Fig. 3 Temperature increment of the Au@PEG-Glc NPrs at different
concentrations under an 808 nm laser.
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increment of the Au@PEG-Glc NPrs can be raised more under
laser irradiation with a higher density. Hyperthermia is known
to induce cell death at temperatures between 42 and 47 °C.57,58
Excessively high temperature would lead to healthy cells being
damaged. Herein, the laser density and NPr concentrations are
chosen for the required temperature rise for more efficient
cancer photothermal therapy.
The photothermal conversion performance of Au@PEG-Glc
NPrs indicates their feasibility as a nanoheater. The bio-
compatibility of nanostructures is also an important issue for
further in vivo applications in imaging and therapy. The cyto-
toxicity of the Au@PEG-Glc NPrs was studied by means of a
MTT assay (Fig. S5†). Cell viability decreased less with an
increase in Au@PEG-Glc NPr concentration, and no obvious
cytotoxicity was observed. Moreover, photothermal perform-
ance was evaluated by investigating the cell viability versus con-
centration of the Au@PEG-Glc NPrs and the irradiation time
(Fig. S6†). With increasing the concentration of Au@PEG-Glc
NPrs or extending the irradiation duration, the cell viability
decreased rapidly. Namely, it depended on both NPr concen-
tration and irradiation duration.
Fig. 4 exhibits the fluorescence live/dead cell staining
experiments performed to observe the photothermal ablation
process. Here, gastric cancer cells are used because gastric
cancer is the third leading cause of cancer-related mortality
worldwide but the efficacy of traditional therapies is not
ideal.1,59 Therefore it is important to improve the treatment
efficacy of gastric cancer through novel biomedical techniques.
Gastric cancer MGC-803 cells were transfected with GFP and
incubated with Au@PEG NPrs and Au@PEG-Glc NPrs under
laser irradiation for 2 min, 4 min and 8 min. Then the cells
were stained with PI to show the changes in the cells. With
extending the irradiation time, the amount of live cells
labelled by green fluorescence decreases, and dead cells
labelled by red fluorescence increases. In comparison, in the
presence of the Au@PEG-Glc NPrs, the mortality of cancer
cells reaches 80% after 4 min of irradiation, and almost 100%
after 8 min of irradiation, indicating that the cancer cells are
effectively killed. Moreover, cells non-treated with NPrs were
unaffected under the same conditions. This result is consist-
ent with the cell viability measured by the MTT assay
(Fig. S6†), illustrating that the Au@PEG-Glc NPrs could
promote cancer cell ablation under laser irradiation efficiently.
In the presence of the Au@PEG NPrs, the mortality of cancer
cells is only about 65% after 8 min of irradiation. This
indicates that the number of Au@PEG-Glc NPrs within the
cells is more than that of Au@PEG NPrs; namely the coating of
glucose facilitates NPrs entering the cells.
The coating of glucose was reported to promote the cellular
uptake of nanomaterials much more than that of unmodified
ones by cancer cells.42 As a carbohydrate, glucose is a funda-
mental source of energy in living cells. Cancer cells undergo
more active metabolism than normal cells, thus taking up
more glucose.60–62 Overexpression of membrane glucose trans-
porters in human cancers also leads to increased glucose utili-
zation in tumor cells.55 ICP-MS measurements indicate that
cancer cells (1 × 106) take up 2.4 times more Au@PEG-Glc
NPrs than Au@PEG NPrs. The modification of glucose efficien-
tly accelerates the accumulation of Au NPrs in tumor cells. For
the Au@PEG NPrs, their accumulation in tumor tissue is
based only on the enhanced permeability and retention (EPR)
effect in solid tumors.63–65 So Au@PEG-Glc NPrs could be
effectively delivered to cancer tissue and spread inside it much
more than Au@PEG NPrs due to the combined influence of
glucose and the EPR effect.
As mentioned above, Au NPrs possess not only photother-
mal conversion performance, but also photoabsorbing
performance as an imaging agent. As shown in Fig. S7,† Au
NPrs exhibit optoacoustic signals that significantly increase
with an increase of Au NPr concentration. Therefore, Au NPrs
can be visualized in vivo to evaluate the circulation time and
accumulation behavior of the Au NPrs inside the tumor
instead of dissecting mice and monitoring them through
ICP-MS measurements, enabling the subsequent therapy to be
guided. Fig. 5 shows the optoacoustic images of the tumors at
Fig. 4 Fluorescence images of cells filled with Au@PEG and
Au@PEG-Glc NPrs under laser irradiation (0 min, 2 min, 4 min, 8 min),
and fluorescence images of cells under laser irradiation (control group,
0 min, 2 min, 4 min, 8 min).
Fig. 5 Optoacoustic signals of the Au@PEG-Glc NPrs in the tumor
region acquired before injection (0 h) and after injection (2, 6, 12, 18 and
24 h). The scale bar is 2 mm.
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different times. Before injection, only the major blood vessels
can be observed. Then, 100 μL (1 mg mL−1) of the
Au@PEG-Glc NPrs were intravenously injected into the
MGC-803 cell tumor-bearing nude mice. The optoacoustic
signals in the tumor region are enhanced much more and the
profile of the tumor becomes clearer with the passage of time.
In comparison, optoacoustic signals of the tumor after injec-
tion of the Au@PEG NPrs are weaker and the profile is less
obvious (Fig. S8†). This demonstrates that the Au@PEG-Glc
NPrs gradually accumulate in the tumor region much more
and that the accumulation process can be observed by opto-
acoustic imaging in vivo.
Based on the optoacoustic imaging technique, photo-
thermal therapy was further assessed in vivo. Nude mice
bearing a MGC-803 tumor model were injected intravenously
with 100 μL of PBS, 100 μL of a 1 mg mL−1 PBS solution of
Au@PEG NPrs and 100 μL of a 1 mg mL−1 PBS solution of
Au@PEG-Glc NPrs. After 24 h the tumors were exposed to an
808 nm laser at a power density of 0.5 W cm−2 for 5 min. As
shown in Fig. 6a, the surface temperature of the tumors was
monitored by a thermal imaging camera. With the injection of
the Au@PEG-Glc NPrs, the temperature rapidly reached above
44 °C in 1 min, and rose to 50 °C in the next 4 min. In
comparison, the temperature of the tumor injected with the
Au@PEG NPrs increased to around 44 °C after 5 min
irradiation (Fig. 6b). This indicates that the coating of glucose
facilitates the accumulation of the Au@PEG-Glc NPrs in the
tumor region and the increase of temperature after the same
irradiation time, thus achieving efficient photothermal
therapy. The obtained highest temperature is controlled
purposely, because heating cells to between 42 and 47 °C leads
to cell death,66 and it is not necessary to generate excessively
high temperatures leading to healthy tissue being seriously
damaged and curable duration extended.
Through the photothermal treatment above, the therapeutic
efficacy of Au@PEG-Glc NPrs is investigated by measuring the
volumes of tumors. After the same duration of laser
irradiation, the tumors on the mice injected with the
Au@PEG-Glc NPrs are completely inhibited and the tumors
disappear and are cured after 12 days (Fig. 7a). No regrowth of
the tumors occurred in two months (Fig. S9†). In comparison,
the tumors on the mice injected with PBS exhibit a rapid
growth. The laser irradiation alone does not have an impact on
the tumor growth. Meanwhile, the tumors on the mice
injected with the Au@PEG NPrs are partly inhibited at first but
could not be eliminated completely (Fig. 7a). This implies that
the photothermal therapy effect of the Au@PEG-Glc NPrs is
much better than that of the Au@PEG NPrs under the same
laser irradiation; namely glucose is beneficial to increase the
Fig. 6 (a) Representative thermal images of tumor-bearing mice
exposed to an 808 nm laser (0.5 W cm−2, 5 min) after injection with
100 μL of PBS (control group), Au@PEG NPrs (1 mg mL−1) and
Au@PEG-Glc NPrs (1 mg mL−1). (b) The corresponding temperature rise
profiles at the tumor site over 5 min of laser irradiation with NPrs or PBS
only.
Fig. 7 Photographs of the tumor mice under different treatments at
different time periods (a). The evolution of the relative tumor volume of
tumor-bearing mice with the injection of different concentrations of
Au@PEG-Glc NPrs (b), and the evolution of the relative tumor volume of
tumor-bearing mice with different irradiation times (c).
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accumulation of the Au@PEG-Glc NPrs in the tumor region
and then enhance the photothermal therapy effect. Further-
more, the tumors on mice with different Au@PEG-Glc NPr
concentrations or irradiation durations were studied and the
tumor sizes were measured by a vernier caliper every two days
(Fig. 7b and c). In contrast, the tumors with an injection of
50 μg mL−1 Au@PEG-Glc NPrs or 3 min irradiation show
slightly slower growth compared to the control group, indicat-
ing that selection of the amount of Au@PEG-Glc NPrs and
irradiation duration affects tumor therapy directly. The
Au@PEG-Glc NPrs possess excellent performance in in vivo
photothermal therapy.
Conclusions
In conclusion, we demonstrate a facile and feasible method
for optoacoustic imaging and photothermal therapy of gastric
cancer by employing Au@PEG-Glc NPrs prepared in aqueous
solution as an imaging contrast agent and hyperthermia
agent. Through a one-pot method, the Au NPrs were syn-
thesized by a stepwise reduction of sodium thiosulfate to
obtain a morphology with a near-infrared absorption property.
In this synthesis method, the non-use of highly toxic surfac-
tants decreases the cytotoxicity efficiently. Glucose is used to
modify the NPr surface, thus they exhibit an excellent bio-
compatibility and cellular uptake. In particular, high accumulation
of the Au@PEG-Glc NPrs in the tumor region is achieved, thus
leading to effective optoacoustic imaging and photothermal
therapy for cancer treatment. Here, a relatively lower tempera-
ture increment of the Au@PEG-Glc NPrs in photothermal
therapy not only avoids damage of healthy tissue, but also pos-
sesses an obvious treatment effect for the tumor. Based on
this, it is possible to apply the as-synthesized nanomaterials in
biomedical imaging, drug delivery, and photothermal therapy.
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